Primary care practices are increasingly joining Independent Physician Associations to strengthen negotiating power with insurers and remain independent.
Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.